The use of PD98059 to antagonize ERK activation after FAM53A overexpression or depletion indicated that FAM53A affects breast cancer proliferation, migration, and invasion via the MEK/ERK signaling pathway. This evidence concerns the gene FAM53A and breast carcinoma.